ARCHIVES

Response From Center Representatives In L.A. To NCI Questions Is “Frusterating,” DeVita Says

This article is from The Cancer Letter archive.

Vol. 10 No. 15 | April 13, 1984

Download PDF Visit The Full Archive

Related Articles

Phase III Xilonix Study Halted Following Unscheduled Analysis

September 26, 2014

In Brief: Reducing Doses Cuts Cure Rate Every Time, DeVita Says; Hyperthermia Use In Cancer Being Assessed

April 6, 1984

First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma

February 22, 2013

Harkin, Hatfield Propose Trust Fund to Raise Research Funding

May 28, 1993

NCI To Conduct Survey On Needs For Compliance with Biohazard Requirements

December 16, 1977

NCCS Networker Volume 4 Issue 1, Winter 1990

January 13, 1990